Friday, 28 Feb 2020

You are here

CDC Reports Increases in Tularemia

The Centers for Disease Control and Prevention (CDC) has reported a sharp rise in tularemia, especially in Colorado, South Dakota, Wyoming, and Nebraska.  As of 9/30/15 a total of 100 cases have been reported, which is up from an annual average of 20 cases seen in these 4 states seen between 2004 to 2014. (Citation source http://buff.ly/1Z4y6jQ)

CDC states approximately 125 cases have been reported annually in the United States during the last two decades (2). As of September 30, a total of 100 tularemia cases were reported in 2015 among residents of Colorado (n=43), Nebraska (21), South Dakota (20), and Wyoming (16).  Overall, 48 persons were hospitalized, and one death was reported.

Tularemia is a rare, serious disease caused by a gram-negative coccobacillus, Francisella tularensis, which infects humans and animals in the Northern Hemisphere.Tularemia can be transmitted to humans by direct contact with infected animals (e.g., rabbits or cats); ingestion of contaminated food, water, or soil; inhalation from aerosolization (e.g., landscaping, mowing over voles, hares, and rodents, or other farming activities); or arthropod bites (e.g., ticks or deer flies).

Symptoms may include fever and chills with muscle and joint pain (typhoidal), cough or difficulty breathing (pneumonic), swollen lymph nodes with or without skin lesions (ulceroglandular or glandular), conjunctivitis (oculoglandular), pharyngitis (oropharyngeal), or abdominal pain with vomiting and diarrhea (intestinal). Symptoms typically begin within 3–5 days of exposure, but can take up to 14 days to appear. Case fatality rates range from <2%–24%, depending on the strain.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Overmedication of America

Recent research from the Lown Institute reports that 750 older Americans are hospitalized daily because of serious side effects from and the core problem is that of polypharmacy, especially in the elderly. 

Best of 2019 - Biologic Safety Guidelines from the British Society for Rheumatology

In the United Kingdom, NICE has looked to the British Society of Rheumatology (BSR) to develop evidence based guidance on the safe use of biologic DMARDs in patients with inflammatory arthritis. This guidance document on biologic safety covers baseline screening, monitoring, effect of co-morbidities, and when or under what circumstances biologic therapy should be interrupted.

Best of 2019 - Methotrexate and the Risk of Lung Disease

Rheumatology has a comprehensive overview of methotrexate (MTX) and the risk of lung injury, MTX-related pneumonitis and interstitial lung disease (RA-ILD) with rheumatoid arthritis (RA). Past reports suggest the frequence of MTX-pneumonitis to be between 0.3 and 11.6%; recent studies suggest it may be much lower.

No Cancer Risk with Systemic Necrotizing Vasculitis

The French Vasculitis Study Group has published that patients with systemic necrotizing vasculitis do not have an increased risk of malignancy; in fact they have a risk that is similar to the general population.

Previous reports have suggested either no risk or a declining risk in the era of better therapies for vasculitis. 

FDA Warns 15 CBD Manufacturers

Today, the U.S. Food and Drug Administration issued warning letters to 15 companies for illegally selling products containing cannabidiol (CBD) in ways that violate the Federal Food, Drug, and Cosmetic Act (FD&C Act).  This warning affirms that the FDA has not determined the many preparations of cannabidiol to be safe or effective.